Stop TB Partnership

Accelerator for Impact (a4i)

a4i aims to accelerate the roll-out of healthtech solutions for TB, other infectious respiratory diseases (i.e., COVID-19) and common TB morbidities (i.e., HIV, diabetes, etc.) in TB affected countries by:

  • Providing expert guidance on product launch and market access;
  • Financing critical activities to generate market demand and maximize roll-out; and
  • Providing visibility and access to a network of in-country and global partners and public and private sector provider networks.

Some of the illustrative activities and support include:

Advisory Service

  • Map landscape of in-country and global partners and public and private sector provider networks
  • Leverage in-country and global partners to establish expansion plan across public and private sector provider networks
  • Support product launch and market access planning by public and private sector provider networks

Technical Support & Evidence Generation

  • Support in-country demonstration studies by in-country partners and public and private sector provider networks

Normative & Policy Guidance

  • Support independent evaluations for World Health Organization’s review and recommendation (if required)

Advocacy

  • Convene focus group discussions, consultations, etc. to increase awareness for and credibility of healthtech solutions with in-country and global partners and public and private sector provider networks

a4i was soft launched in November 2016 after its 1st Stakeholder Consultation, which was held in Liverpool, United Kingdom on 26 October 2016 in advance of the 47th Union World Conference on Lung Health.